Antimicrobial Compounds Ribosome Binding Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of resistant bacterial strains has rendered existing antibiotic agents ineffective, leading to a lack of new antibiotics entering the market, exacerbating the challenge of treating microbial infections, especially as resistance increases in both hospital and community settings.
Innovation Solution
Development of novel antimicrobial compounds with specific chemical structures that inhibit bacterial ribosome function by binding to ribosome sites, utilizing a structure-based drug design approach, which targets resistant strains more effectively than current antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotic agents are used, then treatment of common bacterial infections is effective, but resistant bacterial strains emerge rendering the antibiotics ineffective
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antibiotic compounds through systematic variation of substituents at specific positions (R1-R6 groups) to create new derivatives with altered biological properties. This structural parameter optimization aims to maintain or enhance antibacterial activity while overcoming resistance mechanisms that have rendered existing antibiotics ineffective.
Solution Approach 2:
The invention employs composite material principles by combining multiple substituent groups (halo, alkyl, alkoxy, amino, carboxyl, etc.) in specific configurations around the core chemical structure. These composite molecular structures are designed to achieve synergistic effects that provide both antibacterial activity and resistance to bacterial degradation or efflux mechanisms.
2Reliability
If new antimicrobial compounds are developed through structure-based drug design, then activity against resistant strains is enhanced, but development time and complexity increase
Solution Approach 1:
The patent applies preliminary action by using structure-based drug design approaches where the core molecular framework and key substituent positions are predetermined based on known ribosome binding interactions. This pre-planning of structural elements guides the systematic optimization process, reducing the complexity of de novo drug design while maintaining the ability to target resistant strains effectively.
Solution Approach 2:
The invention segments the molecular structure into distinct functional regions (core structure with defined R1-R6 substituent positions) that can be independently optimized. This segmentation allows researchers to systematically vary specific groups while maintaining the overall molecular architecture, simplifying the development process compared to redesigning entire molecular structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide enhanced activity against resistant bacterial strains, addressing the need for new antimicrobial agents and offering effective treatment, prevention, and risk reduction for microbial infections.
Implementation Method 1
By modulating or inhibiting bacterial ribosome function, antimicrobial compounds could interfere with essential processes such as RNA translation and protein synthesis... some antibiotic compounds such as erythromycin, clindamycin, and linezolid are known to bind to the ribosome
Data Source
AI summary
The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals.